SPECTROModule: A modular in-situ spectroscopy platform for exobiology and space sciences

The evolution of the solar system and the origin of life remain some of the most intriguing questions for humankind. Addressing these questions experimentally is challenging due to the difficulty of mimicking environmental conditions representative for Early Earth and/or space conditions in general in ground-based laboratories. Performing experiments directly in space offers the great chance to overcome some of these obstacles and to possibly find answers to these questions. Exposure platforms in Low Earth Orbit (LEO) with the possibility for long-duration solar exposure are ideal for investigating the effects of solar and cosmic radiation on various biological and non-biological samples. Up to now, the Exobiology and space science research community has successfully made use of the International Space Station (ISS) via the EXPOSE facility to expose samples to the space environment with subsequent analyses after return to Earth. The emerging small and nanosatellite market represents another opportunity for astrobiology research as proven by the robotic O/OREOS mission, where samples were monitored in-situ, i.e. in Earth orbit. In this framework, the European Space Agency is developing a novel Exobiology facility outside the ISS. The new platform, which can host up to four different experiments, will combine the advantages of the ISS (long-term exposure, sample return capability) with near-real-time in-situ monitoring of the chemical/biological evolution in space. In particular, ultraviolet–visible (UV–Vis) and infrared (IR) spectroscopy were considered as key non-invasive methods to analyse the samples in situ. Changes in the absorption spectra of the samples developing over time will reveal the chemical consequences of exposure to solar radiation. Simultaneously, spectroscopy provides information on the growth rate or metabolic activities of biological cultures. The first quartet of experiments to be performed on-board consists of IceCold, OREOcube and Exocube (dual payload consisting of ExocubeChem and ExocubeBio). To prepare for the development of the Exobiology facility, ground units of the UV–Vis and IR spectrometers were studied, manufactured and tested as precursors of the flight units. The activity led to a modular in-situ spectroscopy platform able to perform different measurements (e.g. absorbance, optical density, fluorescence measurements) at the same time on different samples. We describe here the main features of the ground model platform, the verification steps, results and approach followed in the customization of commercial–off-the-shelf (COTS) modules to make them suitable for the space environment. The environmental tests included random and shock vibration, thermal vacuum cycles in the range −20 °C to +40 °C and irradiation of the components with a total dose of 1800 rad (18 Gy). The results of the test campaign consolidated the selection of the optical devices for the Exobiology Facility. The spectroscopic performance of the optical layout was tested and benchmarked in comparison with state-of-the-art laboratory equipment and calibration standards showing good correlation. This includes spectra of samples sets relevant for the flight experiments and a performance comparison between the SPECTROModule ground model and state-of-the-art laboratory spectrometers. Considering the large number of samples and different types of optical measurements planned on-board the ISS, the main outcome was the implementation of an LED-photodiode layout for the optical density and fluorescence measurements of IceCold (42 samples) and ExocubeBio (111 samples); while the UV–Vis spectrometer will be mainly focused on the change of the absorption spectra of the 48 samples of OREOcube.The ExocubeChem samples (in total 48) will be analysed by infrared spectroscopy. The ground platform supports the establishment of analogue research capabilities able to address the long-term objectives beyond the current application

2019 ARIA Care pathways for allergen immunotherapy

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.Peer reviewe

ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.Peer reviewe

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.Peer reviewe

Cabbage and fermented vegetables : From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT(1)R) axis associated with oxidative stress. This leads to insulin resistance as well as lung and endothelial damage, two severe outcomes of COVID-19. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is the most potent antioxidant in humans and can block in particular the AT(1)R axis. Cabbage contains precursors of sulforaphane, the most active natural activator of Nrf2. Fermented vegetables contain many lactobacilli, which are also potent Nrf2 activators. Three examples are: kimchi in Korea, westernized foods, and the slum paradox. It is proposed that fermented cabbage is a proof-of-concept of dietary manipulations that may enhance Nrf2-associated antioxidant effects, helpful in mitigating COVID-19 severity.Peer reviewe

Nrf2-interacting nutrients and COVID-19 : time for research to develop adaptation strategies

There are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor. There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm. They also act on the same mechanisms (mTOR: Mammalian target of rapamycin, PPAR gamma:Peroxisome proliferator-activated receptor, NF kappa B: Nuclear factor kappa B, ERK: Extracellular signal-regulated kinases and eIF2 alpha:Elongation initiation factor 2 alpha). They may as a result be important in mitigating the severity of COVID-19, acting through the endoplasmic reticulum stress or ACE-Angiotensin-II-AT(1)R axis (AT(1)R) pathway. Many Nrf2-interacting nutrients are also interacting with TRPA1 and/or TRPV1. Interestingly, geographical areas with very low COVID-19 mortality are those with the lowest prevalence of obesity (Sub-Saharan Africa and Asia). It is tempting to propose that Nrf2-interacting foods and nutrients can re-balance insulin resistance and have a significant effect on COVID-19 severity. It is therefore possible that the intake of these foods may restore an optimal natural balance for the Nrf2 pathway and may be of interest in the mitigation of COVID-19 severity

CORROSION OF CERAMIC SILICON CARBIDE IN HYDROFLUORIC ACID

Silicon carbide usable in mechanical or electrical engineering is produced in various purity grades and exhibits a large number of crystal structure variants. As for use in the chemical field, it is commonly stated that it is highly resistant in acid media but not suitable for use in alkaline media. This paper discusses the resistance of compact silicon carbide to hydrofluoric acid. The compact silicon carbide has been prepared by sintering using the SSiC method with or without binders based on scandium oxide Sc₂O₃ and calcium fluoride CaF₂. The purest silicon carbide sample of cubic 3C structure sintered without a binder was almost insoluble in hydrofluoric acid. It has been shown, however, that pure silicon carbide is perfectly insoluble in hydrofluoric acid irrespective of the structure variants detected in the samples (3C, 4H, 6H, 15R). The corrosion stability of the compact ceramics is affected by the residual SiO₂ content (together with other impurities) in imperfect SiC preparations, and it is influenced by the choice and chemical properties of the chosen ceramic binder as well

ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy" AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Sante) \nPOLLAR (Impact of Air POLLution on Asthma and Rhinitis)\nGARD Demonstration project

Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care.Peer reviewe